Table 1

Univariate and multivariate models assessing the association between the occurrence of hospitalised COVID-19 and each variable

 Variables Rituximab(n=392) Other bDMARDs(n=724) UnivariateOR of hospitalised COVID-19(95% CrI) MultivariateOR of hospitalised COVID-19(95% CrI)Model #1 MultivariateOR of hospitalised COVID-19(95% CrI)Model #2 bDMARDs (RTX vs other bDMARDs) 8.5 (2.4 to 38.6) Pr (OR >1)≈1.0 7.7 (1.7 to 44.7) 4.4 (1.8 to 11.1) Median age (years) 64 (56–71) 57.3 (47.0–67.0) 1.0 (1.0 to 1.1) Pr (OR >1)≈1.0 1.0 (1.0 to 1.0) 1.0 (1.0 to 1.0) Female 285 (72.7) 426 (58.8) 0.6 (0.2 to 2.0)Pr (OR >1)=0.2 0.5 (0.1 to 2.1) 0.5 (0.2 to 1.0) IA diagnosis RA 366 (95.6) 305 (42.4) RA versus SPA0.3 (0.0 to 1.4)Pr (OR >1)=0.06 RA versus SPA1.0 (0.1 to 7.4) RA versus SPA0.6 (0.1 to 3.7) Spondyloarthritis (including psoriatic arthritis) 0 364 (50.6) RA versus other2.2 (0.4 to 8.7) RA versus other2.3 (0.3 to 13.2) RA versus other2.1 (0.3 to 10.7) Other* 17 (4.4) 51 (7.1) Pr (OR >1)=0.8 Comorbidities† Cardiovascular disease 60 (15.4) 167 (23.1) 0.5 (0.1 to 2.1)Pr (OR >1)=0.2 3.6 (0.9 to 16.6) 2.7 (1.3 to 5.8) Cerebrovascular disease 10 (2.6) 29 (4.0) 0.5 (0.0 to 4.2)Pr (OR >1)=0.3 0.5 (0.0 to 4.0) 0.5 (0.0 to 4.3) Chronic lung disease 92 (23.5) 84 (11.6) 1.9 (0.5 to 6.4) 1.0 (0.2 to 3.9) 1.8 (0.9 to 3.8) Diabetes 48 (12.3) 68 (9,4) 2.8 (0.6 to 9.6)Pr (OR >1)=0.8 1.7 (0.4 to 7.4) 2.1 (0.5 to 5.4) Median BMI (kg/m²) (IQR) 25.8 (23.2–29.4) 27.3 (23.4–31.2) Normal BMI vs BMI >250.2 (0.0 to 1.4)Pr (OR >1)=0.1 Normal BMI vs BMI >250.1 (0.0 to 1.0) Normal BMI vs BMI >250.2 (0.0 to 1.1) BMI >30 kg/m² 67 (24.4) 120 (32.3) Normal BMI vs BMI >300.5 (0.1 to 2.6)Pr (OR >1)=0.2 Normal BMI vs BMI >300.4 (0.1 to 2.9) Normal BMI vs BMI >300.4 (0.1 to 2.2) Treatments Conventional synthetic DMARDs 242 (61.7) 374 (51.7) 0.6 (0.2 to 1.9)Pr (OR >1)=0.2 0.6 (0.2 to 2.1) 0.5 (0.2 to 1.0) Other immunosuppressive agents 7 (1.8) 5 (0.7%) 3.0 (1.4 to 6.5)Pr (OR >1) ≈ 1.0 4.0 (0.5 to 30.4) 2.1 (1.0 to 4.4) Oral glucocorticoids Median dose (mg/day) — (IQR) 1 (0–5) 0 (0–0) No steroids vs 0–10 mg/day3.0 (0.7 to 11.4)Pr (OR >1)=0.9No steroids vs >10 mg/day2.9 (0.3 to 20.5)Pr (OR >1)=0.8 No steroids vs 0–10 mg/day1.7 (0.4 to 7.2)No steroids vs >10 mg/day1.3 (0.1 to 10.9) No steroids vs 0–10 mg/day1.7 (0.4 to 7.5)No steroids vs >10 mg/day1.5 (0.1 to 11.1) No steroids 190 (48.5) 486 (37.1) 0–10 mg/day 114 (29.1) 90 (12.4) >10 mg/day 13 (3.3) 10 (1.4)
• Model #1: weakly informative prior (specifying that 0.05<ORx<20 a priori).

• Model #2: taking into account prior according to a recent publication by Strangfeld et al.3

• Bold indicates statistically significant results.

• *Other IA includes vasculitides n=16, juvenile idiopathic arthritis n=12, connective tissue diseases n=11, polymyalgia rheumatica n=10 and others n=19: uveitis, inflammatory bowel disease, stiff-person syndrome, sarcoidosis, inflammatory myositis, calcium pyrophosphate deposition disease, familial Mediterranean fever, Blau syndrome and McCune-Albright syndrome.

• †Comorbidities: ‘cardiovascular disease’ includes abnormal heart rhythms or arrhythmias, aorta disease, coronary artery disease (narrowing of the arteries), heart attack, heart failure, cardiomyopathy, heart valve disease, hypertension, pericardial disease, peripheral vascular disease; ‘cerebrovascular disease’ includes history of stroke and transient ischaemic attack; ‘chronic lung disease’ includes asthma, chronic obstructive pulmonary disease, interstitial pneumopathy and pulmonary fibrosis, asbestosis, pneumonitis, obstructive sleep apnea–hypopnea syndrome and history of pulmonary embolism; diabetes includes type I and II diabetes.

• bDMARD, biologic disease-modifying anti-rheumatic drug; BMI, Body Mass Index; IA, inflammatory arthritides; RA, rheumatoid arthritis; RTX, rituximab; SPA, spondyloarthr.